Bifogade filer
Nanoform Q3 2025 report day set for November 12th, 2025
Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Nanoform Finland Plc | Press Release | September 26, 2025 at 11:00:00 EEST
Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, will publish its Q3 2025 report November 12th, 2025, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time.
The report day has been advanced from November 20th to November 12th. Nanoform’s management will attend SEB Healthcare Seminar in Stockholm November 13-14th and Jefferies Global Healthcare Conference in London November 18-20th.
For further information, please contact:
Henri von Haartman, Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 8 588 685 70, certifiedadviser@carnegie.se. For more information, please visit www.nanoform.com.